Semaglutide: Looking Beyond the Scale
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Semaglutide research includes outcomes beyond body weight. The SELECT trial examined major cardiovascular events in a carefully defined group of adults. Participants had established cardiovascular disease and overweight or obesity, but no diabetes. Researchers randomly assigned semaglutide or placebo alongside standard medical care. The semaglutide group had fewer events in the combined outcome of cardiovascular death, nonfatal heart attack, or nonfatal stroke during follow-up. This is evidence about clinical events in that population. It does not establish the same benefit for every person, formulation, or indication. Adverse effects remain part of the assessment.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Lincoff et al. (2023): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
https://pubmed.ncbi.nlm.nih.gov/37952131/
Primary human randomized cardiovascular outcomes trial

EVIDENCE LIMITATIONS
The trial studied secondary cardiovascular prevention in people with established disease, not healthy adults generally.
A composite endpoint finding does not prove each individual component improved significantly.
No result is transferred to an unrelated research vial.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Semaglutide: Looking Beyond the Scale